TEPEZZA Market Summary
The TEPEZZA market is expected to witness notable growth over the forecast period, supported by strong adoption, increasing prescriptions, and broader uptake in Thyroid Eye Disease (TED). TEPEZZA remains the first and only FDA-approved therapy specifically indicated for TED, including both active and chronic disease, and has transformed the treatment landscape by addressing the underlying cause of the disease rather than simply managing symptoms. Since its launch, the therapy has demonstrated meaningful clinical benefit in reducing proptosis, diplopia, pain, and other vision-related symptoms, supporting continued physician adoption and sustained patient demand.
Commercially, TEPEZZA has emerged as a major rare-disease asset for Amgen. In Q4 2025, TEPEZZA generated USD 457 million in quarterly sales, while full-year sales grew 3% year over year despite temporary inventory fluctuations. The brand has treated more than 25,000 patients worldwide since launch, reflecting robust market penetration and strong physician confidence in its efficacy profile. Additional growth is expected to come from lifecycle management strategies, particularly the development of a subcutaneous on-body injector formulation, as well as international expansion opportunities in markets such as Japan.
Explore DelveInsight’s Full Coverage on the TEPEZZA Market
TEPEZZA Overview
TEPEZZA is a fully human monoclonal antibody developed by Amgen and originally by Horizon Therapeutics for the treatment of Thyroid Eye Disease (TED), a rare and debilitating autoimmune condition associated with Graves’ disease. The therapy is administered as an intravenous infusion and specifically targets insulin-like growth factor-1 receptor (IGF-1R), which is overexpressed in orbital fibroblasts and immune cells involved in TED pathogenesis.
By inhibiting IGF-1R signaling, TEPEZZA helps reduce inflammation, tissue expansion, fibrosis, and proptosis, thereby improving key TED manifestations such as eye bulging, double vision, pain, and quality of life. The therapy became the first FDA-approved treatment for TED in 2020 following pivotal Phase III OPTIC studies that demonstrated significant reductions in proptosis and clinical activity scores compared with placebo. TEPEZZA has shown durable responses in both active and chronic TED, making it a transformative therapy in this space.
Explore TEPEZZA market trends and future growth outlook
TEPEZZA Mechanism, Clinical Value, and Treatment Impact
TEPEZZA’s targeted mechanism has differentiated it from historical TED management approaches such as corticosteroids, radiation, and surgery, which often offered limited efficacy or addressed symptoms without modifying the underlying disease process. By targeting a root cause of TED, TEPEZZA has established a strong clinical position in a disease area marked by significant unmet need.
TED is a progressive autoimmune disease that can lead to vision-threatening complications, facial disfigurement, pain, and severe quality-of-life impairment. Real-world clinical experience and patient discussions continue to underscore the symptomatic improvements achieved with TEPEZZA, particularly in proptosis, orbital pressure, and pain-related symptoms. Although adverse events such as hearing impairment, hyperglycemia, muscle spasms, and infusion reactions have been reported, the therapy’s overall clinical differentiation continues to support strong physician preference and long-term demand.
TEPEZZA Market Dynamics
The TEPEZZA market is being shaped by a combination of clinical leadership, commercial momentum, lifecycle innovation, and expanding geographic reach. One of the key growth drivers is TEPEZZA’s unique status as the first and only approved therapy for TED, which has allowed it to build a strong foothold in a previously underserved market.
Another major factor supporting growth is sustained commercial performance. TEPEZZA has remained a significant revenue contributor in the rare disease segment, supported by continued volume growth and strong patient demand. In addition, the development of a subcutaneous formulation has the potential to further strengthen the product’s market position by improving convenience and reducing dependence on infusion centers. The therapy’s expansion into international markets, including Japan, is also expected to increase the addressable patient pool and diversify revenue beyond the US market.
TEPEZZA Recent Developments
In April 2026, Amgen announced positive topline results from a Phase III trial evaluating TEPEZZA administered via subcutaneous injection using an on-body injector (OBI) in participants with moderate-to-severe active TED. The study showed a highly significant 77% proptosis responder rate, along with clinically meaningful reductions exceeding 3 mm. This development is particularly important because a subcutaneous formulation could offer comparable efficacy to intravenous TEPEZZA while improving treatment convenience, reducing infusion-center burden, and broadening patient accessibility.
TEPEZZA also expanded its global footprint with approval in Japan in 2024, becoming the first approved TED therapy in Asia. Amgen has estimated that Japan alone has approximately 25,000–35,000 TED patients, including both active and chronic disease populations. Continued expansion into additional international markets could materially increase the product’s long-term commercial opportunity.
TEPEZZA Market Outlook
The TEPEZZA market outlook remains favorable through 2034, driven by sustained uptake in TED, growing physician familiarity, and lifecycle expansion strategies. The therapy has already established itself as a foundational treatment option in Graves ophthalmopathy/Thyroid Eye Disease, and its long-term market trajectory is expected to be supported by both continued commercial adoption and potential improvements in treatment accessibility through alternative formulations.
The introduction of the subcutaneous OBI formulation may represent an important next phase in TEPEZZA’s lifecycle. By offering a more convenient route of administration compared with intravenous infusions, it could enhance patient compliance, expand treatment access, and help preserve TEPEZZA’s competitive advantage as new therapies enter development. At the same time, growing awareness of TED as a chronic and burdensome autoimmune disease is likely to support ongoing diagnosis and treatment demand.
TEPEZZA Competitive Landscape
Although TEPEZZA currently enjoys a unique market position as the only approved TED therapy, the competitive landscape is expected to evolve over the coming years. Emerging therapies in Graves ophthalmopathy may pose increasing competition as more late-stage assets approach launch. As a result, TEPEZZA’s future market leadership will likely depend on its ability to maintain clinical differentiation, demonstrate durable efficacy and safety, and capitalize on lifecycle strategies such as new formulations and geographic expansion.
The TEPEZZA market report also highlights the importance of pricing strategy, reimbursement support, competitive intelligence, and regulatory milestones in shaping future performance. These factors will be central to understanding how TEPEZZA sustains its commercial dominance in an increasingly competitive immunology landscape.
TEPEZZA Analytical Perspective by DelveInsight
The TEPEZZA market report provides a detailed assessment of TEPEZZA in approved indications across the seven major markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. It offers a comprehensive view of current and forecasted TEPEZZA sales through 2034, along with product overview, mechanism of action, dosage and administration, regulatory milestones, research and development activities, SWOT analysis, competitive landscape, pricing and reimbursement analysis, and clinical differentiation versus existing therapies.
The report also includes a detailed clinical assessment of TEPEZZA, covering trial interventions, trial conditions, trial status, and key development milestones. In addition, it evaluates TEPEZZA’s market potential, revenue forecast, competitive positioning, strengths and weaknesses relative to competitors, and broader strategic considerations that may influence its commercial trajectory in Graves ophthalmopathy and related immunological indications.
Discover TEPEZZA market opportunities across the 7MM
Conclusion
The TEPEZZA market is poised for continued expansion through 2034, driven by its strong clinical profile, first-in-class positioning, and sustained commercial performance in Thyroid Eye Disease. As the first and only approved therapy for TED, TEPEZZA has fundamentally reshaped disease management by targeting IGF-1R and addressing the underlying biology of the condition. Its demonstrated ability to improve proptosis, diplopia, pain, and overall quality of life has reinforced physician confidence and supported broad patient uptake.
Looking ahead, the TEPEZZA market is expected to benefit from multiple growth catalysts, including the potential launch of a subcutaneous formulation, continued physician adoption, and expansion into international markets such as Japan and other underpenetrated regions. While emerging therapies may intensify competition over time, TEPEZZA’s established clinical value, market leadership, and lifecycle innovation strategy position it strongly for long-term growth in the TED treatment landscape.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
